A recent article published by NPR does a fantastic job of providing legitimacy to a therapy that has been very popular at our compounding pharmacy, low dose naltrexone (LDN). The volume of scientific information is expanding at an enormous pace, and as a result it is challenge to be aware of all the cutting edge therapies, so it is great when the press helps to raise awareness.
The good news is that the research is there, but often takes time to trickle into the mainstream standard of care. This NPR article relays the experience of living with chronic pain from the “other side" of the story, the non-research side, from the point of view of patients.
The article tells the history of LDN, why it's so promising, and the fact that ONLY compounding pharmacies have the ability to prepare this medication in custom dosage forms to meet patients needs.
Patients and providers can quickly read (or listen) to this news story and understand now low dose naltrexone works and it provides legitimacy in coming from a national news source such as NRP
Dr. Bruce Vrooman, an associate professor at Dartmouth's Geisel School of Medicine, was an author of a recent review of low-dose naltrexone research.
The full text of the NPR News story can be found here: In Tiny Doses, An Addiction Medication Moonlights As A Treatment For Chronic Pain
The compounding pharmacists can assist you with your questions about LDN, for more information contact the pharmacy here or call us at 330-339-4466.
Our next public information session on LDN will be October 3rd, 2019 at 6:30pm at the Hampton Inn Meeting Room 1299 West High Avenue New Philadelphia, Ohio 44663.
Do you have experience with LDN you would like to share?
Autoimmune diseases are a complex group of conditions in which the immune system mistakenly attacks healthy cells and tissues. While treatment options exist to manage symptoms, there is no known cure for autoimmune diseases. However, recent research has shed light on the potential benefits of Low Dose Naltrexone (LDN) in managing these conditions. In this blog post, we'll explore some of the latest research findings on the use of LDN in autoimmune diseases.